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The combination ofB-methoxypsoralen (B-MOP) plus ultra-
violet A light (320-400 nm), termed PUVA, is used in the 
treatment of psoriasis, a hyperproliferative disease of the skin . 
This treatment results in the formation of specific B-MOP 
ad ducts with cellular DNA. We have previously developed 
monoclonal antibodies which recognize these 8pMOP pho-
toadducts. We now report the use of these antibodies in an 
indirect immunofluorescence technique to study human skin 
T he combination of 8-methoxypsoralen (8-MOP) and ultraviolet A irradiation (UVA, 320-400 nm) is used clinically in the treatment of a number of different skin diseases including psoriasis and vi tiligo [I). In the United States, at least 20,000 individuals each year arc 
exposed to this therapeutic regimen, called PUVA (psoralen + 
UVA). The use of PUVA throughout the industrialized world is 
thought to be of similar prevalence. More recently, the use of 
8-MOP and UVA has been expanded with the introduction of a 
photochemotherapy process in which the blood of cutaneous T-cell 
lymphoma (CTCL) patients is irradiated extracorporeally [2]. 
When photoactivated with UVA light, 8-MOP reacts with py-
rimidine bases, primarily thymine. in cellular DNA. PsoraJens are 
bifunctional ON A reagents which form three distinct types of pho-
toadducts. two monoaddition products, and one cross-linked prod-
uct. HPLC analysis of DNA modified in vitro with PUVA has 
shown that the 4', 5'thymine Illonoadduct is the predominant pho-
toad duct [3,4]. In vitro studies have shown that these photoadducts 
arc mutagenic [5,61. induce single srrand breaks in DNA [7}. and 
induce chromosomal damage [8.9]. In vivo, squamous and basal cell 
carcinomas of the skin have occurred in animals treated with PUV A 
[10,11 J. Several case reports and epidemiologic studies have sug-
gested that PUV A treatment is carcinogenic in humans [12 - 141. A 
recent 16-center PUV A follow-up study reported that high doses of 
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rcs: fetal calf serum 
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8·MOP: 8.rnethoxypsoralen 
PBS: phosphate buffered saline 
RIA: radioimmunoassay 
biopsies. Nuclei in 3 of5 ski n biopsies from psoriasis patients 
undergoing PUV A therapy were positive for ad ducts. The 
presence of adduces by immunofluorescence did nOt correlate 
with plasma levels of B-MOP. Enzyme-linked immunosor-
bent assays, used to determine whether B-MOP phoroadduces 
could be detected in DNA isolated from the lymphocytes of 
psoriasis pariems after PUVA therapy, were negative.) lUllest 
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PUV A over a 3 - 7 yr period increase the risk of cmaneous squamous 
cell carcinoma tenfold [15]. In contrast. European studies It 6.17] 
have shown an increased risk of squamous cell carcinoma only in 
patients also exposed to ionizing radiation and arsenic. 
It is now possible to detect and quantitate DNA damage by im-
munologic techniques. Specific antibodies have been developed to a 
number of carcinogen-DNA adducts [181. These antibodies have 
been used in highly sensitive immunoassays such as RIA or ELISA to 
quantitate adducts, while immunofluorescence studies have pro-
vided infonnation about tissue localization in animals treated with 
carcinogens (19). [n addition, these antibodies have been used to 
moniror adduct levels in humans exposed to environmental carcin-
ogens and cancer chemOtherapeutic agents [20]. We have pre-
viously developed monoclonal antibodies that bind to DNA modi-
fied by PUVA bue nOt to non-modified DNA or free 8-MOP [21 J. 
Characterization of these antibodies indicated preferential reaction 
with the 4', 5'thymine 11lonoadduct. Recently, we have detected 
8-MOP-DN A adducts in skin biopsies from rats and mice created 
with PUVA by indirect immunofluorescence methods [22J. In ad· 
dition, adducts on DNA isolated from animal skin were quantitated 
by competitive ELISA. Others have used a polyclonal antibody to 
8-MOP DNA [23] to det~ct adduces in animal and human samples 
treated in vitro 124]. Here we have applied th~se techniques to the 
dctcction of 8-MOP-DNA adduct5 in PUVA patients. 
METHODS 
Study Subjects and Specimen Collection Initial development 
of indirect ill1munofluor~sccnce techniques for identification of 
8-MOP-DNA adducts was performed on biopsies frol11 a volunteer. 
Two 4-mm punch biopsies "'''ere taken from the inner forearm of a 
volunteer 30 min after {opical application of a solution of 8-MOP 
(30 III 0.1% solution per 4 cm2). One biopsy was split and, with the 
epidermal side up, irradiated in vitro with 2 or 22 J/cm2. The second 
biopsy was nOt irradiared. All biopsies were snap frozen in OCT 
compound (Lab-Tek Products, Naperville, IL). 
Study subjects wcre five psoriasis patients who were undergoing 
treatment with PUV A by standard protocols 111. Patients took the 
drug (30-60 mg, -0.5 mg/kg) orally and 2 h larer, after absorption 
and circulation of the drug, their skin was irradiated with 4-12 
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Table I. Levels of Free 8-MOP in Plasma and Detection of 8-MOP-DNA Adducrs in Skin 
Biopsy Samples of Psoriasis Patients Given PUV A Therapy 
Dosage 
Patient 8-MOP UVA Frequency Total No. of 8-MOP Plasma uveb Immunofluorescence 
Age/ Sex (mg) ) /cm' of Treatment Treatments (ng/ml') in skin biopsy" 
1 32/ M 30 5.0 1/ week 186 ND' + 
2 42/ M 60 II 2/ week 30 104+/-3 
3 45/ M 60 4.5 1/2 weeks 116 42+/ -12 
4 64/ M 40 9.0 1/ week 61 95+/-7 + 
5 28/ M 40 5.5 1/ week 27 17+/-2 + 
, 8·MOP plasma l~\lels were det~rmined by wlid ph:lSC utractlon of 8MOP from the pl:lSma follow~d by HPLC quantlflUlon. 
b Immunofluorescentt staining is as delCribcd in Fig I. Biopsi~ w~r~ taken within 20 min of irradiation wilh UVA. 
~ NO: not delermined. 
1/cm2 UVA (Table I). After informed consent had been obtained, 
3-mm punch biopsies were obtained from uninvolved skin of the 
trunk. within 20 min after irradiation. Biopsies were snap frozen in 
OCT compound. At the same time the biopsy was obtained, 35 ml 
of blood was collected into heparinized tubes and plasma, an.d buffy 
coat and red blood cells were separated and immediately frozen at 
-70"C until analyzed. 
Indirect Immunofluorescence Techniques Skin biopsies were 
sectioned (4 mm) on a cryostat (American Optical, NY). placed on 
glass microscope slides, fixed with 70% ethanol for 30 min, and air 
dried. 
Both a standard and an "enhanced" indirect immunofluorescence 
(IF) technique were used to identify adducts in tissue sections. In the 
standard technique, fixed, dried sections were washed two times for 
15 min in PBS. then incubated for 30 min at 37"C with hybridom:l 
supernatant of 8-MOP-DNA specific antibody (9D8) diluted I : 10 
in PBS with 20% FCS and containing 0.05% Tween [21]. Afrer 
washing for 15 min with PBS, the sections were incubated for 30 
min at 37°C with a goat anti-mouse 19G antibody conjugated with 
fluorescein isothiocyanate (Southern Biotechnology, Binningham, 
AL) diluted I: 10 in PBS-Tween with 20% FCS. After a final 15 
min wash in PBS, coverslips were applied over a mounting medium 
(50 mM Tris. pH 8.5: glycerol. 8: I ) containing p-phenylenedi-
amine (1 g/l), a chemical that prevents fading of fluorescence. 
An "enhanced" indirect IF technique. which rrovides increased 
sensitivity and detects lower levels of adducts [22 was similar to the 
standard technique with the following changes: The fixed, PBS-
washed skin secrions were incubated wirh RNase A (100 Jig/ ml 
PBS) at 37"C for I h,foJlowed by two !O min PBS washes. Sections 
were then treated with proteinase K (10,ug/ml PBS) at room tem-
perature for 10 min, washed in PBS. and then incubated in 4N HCI 
for 20 min at room temperature. After two 10 min washes in PBS, 
sections were incubated for 30 min at 37°C with 9D8 monoclonal 
antibody dilured 1: 4 in 20% FCS in PBS-Tween. After washing 
with PBS, the sections were then incubated for 30 min at37"C with 
goar anti-mouse IgG antibody conjugated with fluorescein isothio-
cyanate diluted 1: 40 in PBS-Tween with 20% FCS. 
Controls used in the indirect IF procedures included sections of 
a-MOP treated, unirradiated skin and sections of 8-MOP-treated, 
UVA irradiated skin incubated with DNase (IOOl'g/ml PBS) for 30 
min at 37 °C. Specific antibody 9D8 preabsorbed with 8-MOP-
DNA and a non-specific monoclonal antibody hybidoma superna-
tant recognizing acetylaminofluorene-DNA adducts [25] were also 
employed as controls in the indirect IF techniques. 
Competitive Enzyme Linked ImmuDosorbent Assay 
(ELISA) For quanritarion of adducrs by ELISA another monoclo-
nal antibody (8G I ) which also recognizes 8-MOP-DNA adducts is 
routinely used 121]. DNA was isolated from buffy coat cells by 
standard chloroform and phenol extractions and RNase treatment. 
For the competitive ELISA with fluorescence endpoint detection, 
polystyrene U bottom black plates (MicroFLUOR-B, Dynatech 
Laboratories, Inc., Alexandria, Va) were coated with 0.5 ng dena-
tured 8-MOP-DNA per well by drying PBS solutions at 37'C 
overnight. After the plares had been washed with PBS-Tween 
(0.05%) (Multiwash. Flow Laboratories, Mclean, Va), wells were 
incubated with 200,tt1 1% FCS in PBS-Tween. For the srandard 
curve, serial dilutions of in vitro modified 8-MOP-DNA (50 }ll) 
were mixed with the diluted antibody 8GI (I: 6 X 10',501'1) and 
added to the plate. DNA isolated from the patient'S lymphocytes 
was assayed by mixing 50 I'g (50 1'1) with 50 1'1 antibody. The 
amigen-antibody mixtures were incuba[C~:d on rhe plate at 37'"C for 
90 min, then the plates were washed. Goat anti-mouse IgG-alkaline 
phosphatase conjugate was then added (IOO 1'1 . I: 500) and incuba-
tion continued for another 90 min. The wells were rhen washed 
with PBS-Tween and with a.OIM diethanolamine buffer, pH 8.6. 
The substrate was 4-methylumbelliferyl phosphate (50 I'g/ml 
O.1M diethanolamine. pH 9.6). Fluorescence was read on a 96 well 
Auorcscence reader (Micro Fluor; Dynatech Laboratories, Alexan-
dria. VA). 
HPLC Quantitation of Free 8-MOP Plasma levels of 8-MOP 
were quantitated as described [26]' Plasma was passed through a 
CI8 cartridge (Analytichem IntI.. Harbor Ciry. CAl followed by 
washing with PBS. Free 8-MOP was duted with 70% ethanol in 
water. The 8-MOP was quantitated by reverse fhase HPLC (Spec-
tra Physics. San lose. CAl on a Sepralyte Pheny column (Analytic-
hem) with 45% acetonitril e, 55% 0.05M ammonium acetate. A 1 
J1S/ Ji.I stock solution of8-MOP was used [ 0 calibra te the integrator. 
RESULTS 
In skin biopsies from a volunteer treated with topical 8·MOP fol-
lowed by in vitro irradiation of the biopsy with UV A, specific 
nuclear staining was visible in the stratified squamous epithelium of 
the epidermis after both exposure to 22 l /cm' (Fig 10) and 21/ cm2 
(nor shown). No staining was visible in the cytoplasm of these cells 
or in cells in the dermis. A control section was treated with non-spe-
cific antiserum. and the fluorescein conjugated second antibody was 
negative (Fig 1 b). Other controls, including treatment of the section 
with DNase or preabsorption of the antiserum with 8-MOP-DNA 
before use, were negative (not shown). The biopsy treated with 
8-MOP bur no UVA was also negative (not shown). 
Skin biopsies were obtained from patients treated with PUVA for 
various periods at the time of biopsy (Table I). and adducts were 
visualized using an "enhanced" IF technique. Specific epidermal 
nudear staining was detected in three out of five of the biopsy 
sections. Patient 4 had the strongest immunofluorescence staining 
(Fig 2a). The controls, sections from the same individual stained 
with a non-specific monoclonal antibody, were negative (Fig 2b). 
Unfortunately, this trearment tended to disrupt the morphology of 
the skin sections and thus made identification of the cdl types diffi-
cult. 
Differences in skin DNA adduct levels berween patients could be 
due to differences in the levels of free 8-MOP circulating in rhe 
blood at the rime of exposure to UV A. Ir is known that after oral 
administration of a-MOP, plasma levels can vary depending on 
individual rates of absorption and excretion [27]. Plasma levels of 
free 8-MOP were, therefore, measured by solid phase absorption of 
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Figure 1. Indirect immunofluorescence staining of a humlln skin biopsy from a volunteer treated topically with 8-MOP (30ltl 0.1 % solution per 4 cm2) and 
biopsied 30 min later. The biopsy was irradiated in vitro with the epidermal side up with 22 J / cm2• Sections were treared with antibody 908 (1 : 10) and goat 
llnfi-mouse IgG antibody conjugated with fluorescein (1: to),A: biopsy stained with specific llntiserum; B: biopsy stained with non-specific antiserum, 
Figure 2. Indirect immunofluorescence staining of human skin biopsies from a psoriasis patient (#4) treated in vivo with PUVA, Slides were treated with 
RNase A, proteinase K, and 4N Hel before staining with antibody 908 (1: 4) and goat anti-mouse IgG llntibody conjugated with fluorescein (1: 40). A: 
biopsy stained with specific antiserum; B: staining with non-specific antiserum. 
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rhe drug. followed by quanrirarioll by HPLC, and found to range 
from 17 -104 ng/ml (Table I). Drug plasma levels were nOt. how-
ever, related to positive immunofluorescence, becausc the patient 
wIth the highest plasma level offrce 8-MOP did not have detectable 
immunofluorescence. 
We were also interested in determining whether 8-MOP-DNA 
adduces could be detected in the circulating lymphocytes of the 
psoriasis patiencs. DNA was isolated from the white blood cells of 
the five treated patients and assayed by a competitive ELISA with 
fluorescence detection. All samples were negative. indicating that 
the level must be below one adduct in lOS nuclcotidcs, the limit of 
sensitivity of the assay. 
DISCUSSION 
These studies demonstrated that PUVA treatment resultcd in detec-
table levels ofB-MOP-DNA adducrs in the skin of three out of five 
psoriasis patients tested. In our initial immunofluorescence studies 
111 animals. DNA was isolated from skin samples. and adduct levels 
were quanritated in a competitive ELISA with adduct-specific anti-
body. The lowest level of adducts which gave positive immunofluo-
resccncc staining was 2.9 adducts/106 nucleotides 122]. Based on 
our animal experimefl[s. we estimate the extent of DNA modifica-
tion in the positive psoriasis patients to be in the range of one 
psoralcn adduct per 106 nucleotides. Immunofluorescence detection 
is less sensitive than competitive ELISA. which can detect one ad-
duct/ t 08 nucleotides. Unfortunately, we could nOt obtain sufficient 
amoums of DNA from the skin biopsies for testing by ELISA. No 
correlation was seen betwccn plasma levels of8-MOP or total num-
ber of tre'l.[mems and positive immunofluorescencc. Perhaps other 
factors such as variation in DNA repair or skin pigmentation, which 
influcnccs UVA absorption, influence the extent of DNA adduct 
formation. In addition, all samples were from patiems undergoing 
multiple treatments, and it is not known whether ad ducts would bc 
dctectable after a single exposure; nor is it known whether adduct 
levels decrease bcrween rreatments. 
Previous studies have indicated that patients undergoing PUVA 
therapy for t - 6 yr have a small bur stacistically significant increase 
in levels of sister chromatid exchange in their peripheral lympho-
cytes [28]. Another srudy demonstrated an increased level of mutant 
lymphocytes in PUVA patients [291. These srudies suggested that a 
significant fraction of the administered UV A radiation can reach the 
pcripherallymphocytes. However, our studies indicated that adduct 
levels in the circulating lymphocytes of PUV A treated pacients arc 
below t/10" nucleotides. Lymphocytes are exposed to approxi-
mately 1%-5% of the skin surface dose of UVA [30]. Prolonged 
treatment results in skin pigmentation and may, therefore, decrease 
the effective UVA dose. Because we estimate that the level of DNA 
adducts in the skin of created patients is about one adduct per 106 
nucleorides, adduct Icvels in lymphocytes would bc expected to be 
less than l/tOK• These results can be contrasted to adduct levels 
detected in the lymphocytes of CTCL patients treated by extracor-
poreal phorophoresis [31]. In these studies, blood samples were di-
reedy collected from the photopheresis apparatus. As expected, 
With in vivo irradiation oflymphocytes high levels of ON A adduces 
were formed, in the range of o. t to 15 adducts/ t 06 nucleotides. 
While some studies have indicated an increased risk of squamous 
cell carcinoma of the skin in PUVA patients. there have only been 
isolated case reports of internal tumors [32]. A variery of mecha-
nisms have been proposed for PUV A induced cancers. These in-
clude its Illucagenic effects [33J, alterations in the immune response 
[341. and persistent hypermutability [35]. The studies presented 
here provide direct evidence that DNA damage has occurred in the 
epidermal cells of PUV A treated patients, and suggest that the in-
creased risk of skin cancer may be due to the DNA damaging effects 
of PUVA. DNA adduct detection may allow the determination of 
adduct levels required for clinical response and adjustment of these 
levels to maximize response while minimizing the potencial risk for 
cancer development. In addition, biologic moniroring of PUVA 
patients Illay contribute to an understanding of the relationship of 
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DNA adduct levels to cancer risk. and thus contribute to the general 
area of carcinogen risk assessment. 
TJ,~ al/thon ~xpms thdr appmialiofl to R. Yaflgjor SLtrl!taria/ assistarlct. 
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